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EpidemiologyAims: Taller stature has been associated with increased risk of atrial fibrillation (AF). AF and heart failure
(HF) often co-occur but the association between height and risk of HF in older adults has not been well
studied. We have examined the association between height and incident AF and incident HF in older
adults.
Methods: Prospective study of 3346 men aged 60–79 years with no diagnosed HF, myocardial infarction
or stroke at baseline (1998–2000) followed up for a mean period of 16 years, in whom there were 294
incident HF cases and 456 incident AF. Men were divided into 5 height groups: <168.2, 168.2–172.5,
172.6–176.9, 177.0–183.0 and >183.0 cms based on the 25th, 50th, 75th and 95th centiles distribution
of height.
Results: CVD risk factors tended to decrease with increasing height but a positive association was seen
between height and electrocardiographic QRS duration and incident AF. Both short stature (<168.2 cm)
and tall stature (>183.0 cm) was associated with significantly increased risk of HF in age-adjusted anal-
ysis compared to those in the second height quartile [HR (95 %CI) = 1.62 (1.15, 2.26) and 2.04 (1.23, 3.39)
respectively]. In short men the increased risk remained after adjustment for adverse CVD risk factors; in
tall men the association was largely associated with AF and QRS duration.
Conclusion: Tall stature is associated with significantly increased risk of AF leading to increased risk of HF.
Short stature was associated with increased HF risk which was not explained by known adverse CVD risk
factors.
 2021 The Authors. Published by Elsevier B.V. This is an open access articleunder the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Atrial fibrillation (AF) is the most common heart rhythm disor-
der in older adults and is strongly associated with heart failure
(HF) [1]. Although short stature has been associated with increased
risk of coronary heart disease [2], previous observational studies
have consistently shown tall stature to be associated with
increased risk of AF [3–9] and a recent large Mendelian Random-
ization Study suggest that the association is causal [10]. Moreover,recent studies have reported associations between tall stature and
abnormal electrocardiographic repolarisation markers such as the
QRS duration [11–13] which have been associated with incident
AF and HF [14–17]. Relatively few studies in western populations
have investigated the association between height and develop-
ment of HF and in the few that have the findings have been incon-
sistent. In middle-aged populations, two studies showed an inverse
association between height and incident HF risk [7,18], while one
study reported no significant association between height and HF
although the highest risk was observed in tall adults [19]. The
lower risk of HF in tall adults reported in middle-aged populations
may reflect the reduced risk of coronary heart disease associated
with greater height [2]. Incidence of AF increases steeply with
age and is a major contributor to HF in older adults. The inverse
association between height and HF risk reported in younger popu-
lations may not apply in older people in whom HF is often not pre-
ceded by a myocardial infarction (MI). Thus we hypothesised that
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adults. We have therefore examined prospectively the association
between adult height and incident AF and incident HF in a popula-
tion based cohort of older men.2. Subjects and methods
The British Regional Heart Study is a prospective study of car-
diovascular disease involving 7735 men aged 40–59 years drawn
from general practice in each of 24 British towns, who were
screened between 1978 and 1980 [20]. The population studied
was socio-economically representative of British men but con-
sisted almost entirely of white Europeans (>99%). In 1998–2000,
all surviving men, then aged 60–79 years (mean age 68.7 years),
were invited for a 20th year follow-up examination and 4252
men (77% of survivors) attended for examination. The men com-
pleted a questionnaire which included questions on their medical
history and lifestyle behaviour. They were requested to fast for a
minimum of 6 h, during which time they were instructed to drink
only water and to attend for measurement at a pre-specified time
between 0800 and 1800 h. All men were asked to provide a blood
sample, collected using the Sarstedt Monovette system. The proto-
col complied with the Declaration of Helsinki of 1975 (as revised in
1983) and all relevant local research ethics committees provided
ethical approval. In 2010–2012 surviving study members aged
71–92 years (n = 3137) were invited to attend a 30-year re-
examination, of whom 1722 attended a physical examination
(55% response rate).
2.1. Cardiovascular risk factor measurements at 1998–2000
Anthropometric measurements including body weight, height
and waist circumference were carried. Details of measurement
and classification methods for smoking status, physical activity,
social class, alcohol intake, blood pressure and blood lipids in this
cohort have been described [21,22]. Heavy drinking was defined as
drinking more than five units (1 UK unit = 10 g) of alcohol daily on
most days. The men were also asked to report their pattern of
physical activity such as walking, cycling and other sporting activ-
ities. Physical activity scores were assigned on the basis of fre-
quency and type of activity and the men were divided into 6
groups: none, occasional, light, moderate, moderately-vigorous
and vigorous. Subjects who reported none or occasional activity
were classified as ‘inactive’. Social class was derived from the long-
est held occupation recorded at the time of baseline questionnaire
(1978–80) using the Registrar General’s classification of occupa-
tions, with categories grouped as non-manual (I, II and III non-
manual) and manual (III manual, IV and V). Predicted glomerular
filtration rate (eGFR) (measure of renal function) was estimated
from serum creatinine using the equation eGFR = 186  (creatinin
e)-1.154  (age)-0.203 [23]. Renal dysfunction was defined as
eGFR < 60. N-terminal pro-brain natriuretic peptide (NT-proBNP)
and high sensitive troponin T (hsTnT) were determined using the
Elecsys 2010 electrochemiluminescence method (Roche Diagnos-
tics, Burgess Hill, UK) [24].
2.2. ECG measurements
At both re-examinations in 1998–2000 and 2010–2012 12 lead
electrocardiograms were recorded using a Siemens Sicard 460
instrument and were analyzed at the University of Glasgow ECG
core laboratory using Minnesota Coding definitions [25]. Prolonged
QRS duration was defined as values > 100 ms and abnormal as
>=120 ms [26]. Electrocardiographic left ventricular hypertrophy
(LVH) was defined according to relevant Minnesota codes (codes2
3.1 or 3.3). AF was defined according to Minnesota codes 8.3.1
and 8.3.3.2.3. Follow-up
All men have been followed up from initial examination (1978–
1980) for cardiovascular morbidity [20] and follow-up has been
achieved for 99% of the cohort. In the present analyses, all-cause
mortality and HF events are based on follow-up from re-
examination in 1998–2000 at mean age 60–79 years to June
2016. Survival times ended at the first HF event or when they were
censored for death due to any cause, or the end of the follow-up
period (June 2016), whichever occurred first. Information on death
was provided by the UK National Health Service registers. Fatal
CHD events were defined as death with CHD (ICD 9th revision,
codes 410–414) as the underlying code. A non-fatal MI was diag-
nosed according to World Health Organisation criteria. Evidence
of non-fatal MI and HF was obtained by ad hoc reports from gen-
eral practitioners supplemented by biennial reviews of the
patients’ practice records (including hospital and clinic correspon-
dence) through to the end of the study period. Incident CHD
included fatal CHD and non-fatal MI. Incident non-fatal HF was
based on a doctor-confirmed diagnosis of HF from primary care
medical records (including hospital and clinical correspondence)
[24]. All cases were verified by a review of available clinical infor-
mation from primary and secondary care records (symptoms,
signs, investigations, and treatment response) to ensure they are
consistent with current recommendations on HF diagnosis [27].
Incident fatal HF cases were those in which the diagnosis of HF
was mentioned as the underlying cause of death at death certifi-
cates (ICD 9th revision code 428). Incident HF included both inci-
dent non-fatal HF and incident fatal HF.2.3.1. Incident Atrial fibrillation
Incident AF was obtained from ad hoc reports from general
practitioners supplemented by reporting of medication for AF by
the men on follow-up questionnaires or evidence of AF on ECG at
the 30-year examination. The men were asked about medication
and the reason for taking the medication. Only men who reported
medication for treatment of AF specifically were included. Patient
reporting of medication for AF was confirmed in 77% of cases.2.4. Statistical analysis
The men were initially divided into 4 groups based on quartiles
of the height distribution. Because of the interest in very tall adults
we separated out the top 5% of men in the height distribution and 5
height groups were used. Cox’s proportional hazards model was
used to assess the multivariate-adjusted hazards ratio (relative
risk) for HF and incident AF in a comparison of 5 height groups:
<168.2, 168.2–172.5, 172.6–176.9, 177.0–183.0 and > 183.0 cms
using the 2nd quartile as the reference group. Restricted cubic
splines were used to visually depict the association between height
and incident HF. In multivariate analyses, smoking, social class,
physical activity, alcohol intake, diabetes, use of antihypertensive
treatment, renal dysfunction were fitted as categorical variables;
CRP, systolic blood pressure, waist circumference and QRS duration
were fitted as continuous variables. Adjustment for incident AF
was fitted as a time dependent covariate. In the analysis assessing
height and incident AF, all men with prevalent AF (N = 78) were
excluded.
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From the 4252 men examined in 1998–2000 we excluded men
with doctor diagnosed MI, stroke or HF. After these exclusions
3346 men were available for analysis. During the average follow-
up period of 16 years there were 294 incident HF cases in the
3346 men with no previous history of HF, MI or stroke.
3.1. Baseline characteristics
Table 1 shows baseline characteristics in the study population
by the 5 height groups. Short men tended to have more adverse
risk factors than taller men. They were older and had the highest
rates of smoking, physical inactivity and use of antihypertensive
drugs and were more likely to be manual workers. They had the
highest levels of systolic blood pressure, inflammation (CRP),
vWF, heart rate, NT-proBNP and hsTnT, evidence of ischaemia
and the lowest level of lung function. However, positive associa-
tions were seen between height, AF and QRS duration, with the tal-
lest men having the highest prevalence of AF and longer mean QRS
duration. The positive associations between height and AF and
height and QRS duration remained significant even after adjust-
ment for age and BMI and were independent of each other. In
mutually adjusted analyses also including age and BMI, the odds
of having AF for the tallest men compared to the reference group
was 4.52 (1.97,10.37) and the odds of having an abnormal QRS
duration was 2.01 (1.22,3.29).
3.2. Height and incident AF
There were 456 incident AF cases in the 3268 men with no
prevalent AF. Table 2 shows the association between height and
incident AF. Risk of developing AF increased with increasing height
with the tallest men having nearly a two fold increase in risk ofTable 1
Baseline characteristics by height in 3346 men without prevalent HF, MI or stroke.
H
<168.2 168.2–172.5 1
N = 841 N = 829 N
Age 69.5 (5.7) 68.9 (5.5) 6
WC 94.2 (10.2) 96.3 (9.4) 9
BMI 26.80 (3.79) 26.77 (3.39) 2
% obese 16.6 15.2 1
% smokers 15.6 12.9 1
% manual workers 65.5 55.8 5
% heavy drinking 3.8 3.8 3
% inactive 36.7 33.8 3
% BP loweringdrugs 29.5 25.4 2
% diabetes 11.8 11.2 1
% CKD 17.0 13.4 1
Biological markers
SBP (mmHg) 152.1 (24.5) 149.8 (24.5) 1
Cholesterol (mmol/l) 6.10 (1.10) 6.08 (1.06) 6
HDL-C (mmol/l) 1.35 (0.35) 1.32 (0.33) 1
CRP (mg/L)* 1.90 1.68 1
vWF ((IU/dl) 143.2 (46.5) 139.0 (44.4) 1
FEV1 (L) 2.31 (0.61) 2.56 (0.65) 2
Heart Rate (b/min) 66.9 (12.0) 66.7 (13.3) 6
NT-proBNP (pg/ml)* 95.6 81.58 8
hsTnT (pg/ml)* 12.06 11.58 1
ECG parameters
% AF 2.8 2.0 3
% LVH 8.4 8.7 6
% evidence ischaemia 25.2 23.0 1
QRS duration 9.69 (1.67) 9.89 (1.83) 1
%>100 ms 22.2 27.8 3
%120 ms 6.8 9.3 1
* Geometric mean
3
developing AF compared to the reference group. This was seen
even after adjustment for a wide range of possible confounders
including age, smoking, physical inactivity, heavy drinking, social
class, waist circumference, blood pressure, cholesterol, FEV1, renal
function, diabetes, use of antihypertensive drugs, LVH and CRP and
QRS-duration.
We carried out a sensitivity analysis restricted to those with
ECG evidence of AF based on a subgroup of men (n = 1348) who
attended both the 1998–2000 and the 2010–12 re-examination.
The results confirmed the highest risk of AF seen in the tallest men.3.3. Height and incident HF
In age-adjusted analysis, tall stature in particular, as well as
short stature was associated with significantly increased risk of
HF with the lowest risk in men in the second quartile (Table 3).
The increased risk seen in short men remained after adjustment
for lifestyle characteristics, established CHD risk factors and CRP.
Since tall men had the most favourable CHD risk factors, adjust-
ment increased the risk further (Table 3; model 1). Fig. 1 shows
the continuous association between height and risk of HF after
these adjustments. Further adjustment for prevalent AF and QRS
duration attenuated the increased risk seen in tall men (Table 3;
models 2 and 3). Of the men who developed HF during follow-up
58 men (20%) had developed AF prior to the HF event. Comparisons
between the height groups showed that 11.4% (n = 10) of HF cases
was preceded by incident AF in short men compared with 33.3% of
cases (n = 7) in the tall men. Thus the increased risk of HF in the tall
men was attenuated further after taking into account men who
developed AF (Table 3; model 4). Short stature remained signifi-
cantly associated with increased risk of HF after adjustment and
was strengthened after adjustment for incident AF.eight (cm)
72.6–176.9 177–183.0 >183.0 p-trend
= 849 N = 650 N = 177
8.1 (5.3) 67.2 (4.9) 66.3 (4.9) <0.0001
7.44 (10.1) 98.85 (9.9) 101.6 (11.4) <0.0001
6.80 (3.68) 26.74 (3.43) 26.77 (3.53) 0.78
5.3 14.9 15.3 0.20
0.8 13.6 6.9 0.009
0.2 42.2 37.1 <0.0001
.7 4.6 4.0 0.64
0.8 27.7 31.0 0.0002
7.6 23.8 25.7 0.06
1.8 12.5 13.1 0.48
3.9 10.5 15.4 0.01
49.9 (23.3) 148.9 (22.6) 146.0 (23.1) 0.001
.09 (1.05) 6.02 (1.05) 5.82 (0.92) 0.01
.34 (0.35) 1.32 (0.33) 1.32 (0.34) 0.12
.58 1.51 1.36 <0.0001
35.3 (46.0) 131.2 (42.0) 132.4 (47.1) <0.0001
.70 (0.65) 2.88 (0.72) 3.11 (0.72) <0.0001
4.9 (12.2) 65.3 (12.9) 63.6 (13.2) <0.0001
2.3 83.1 83.1 0.04
1.47 11.02 11.02 0.0002
.1 2.6 5.7 0.18
.7 6.2 5.1 0.02
8.3 19.6 17.7 0.001
0.05 (1.81) 10.05 (1.64) 10.32 (1.85) <0.0001
4.1 35.2 54.3 <0.0001
0.6 9.1 13.7 <0.0001
Table 2
Height and adjusted hazards ratio (95 %CI) incident AF in 3268 men with no prevalent AF, HF, stroke or MI.
HR (95 %CI)
Height (cms)
<168.2 168.2–172.5 172.6–176.9 177.0–183.0 >183.0 Linear trend
No of men 822 817 827 655 167
Incident AF % (n) 8.3 (68) 13.6 (111) 14.2 (117) 19.4 (123) 22.2 (37)
Age-adjusted 0.63 (0.47,0.85) 1.00 1.03 (0.79,1.33) 1.45 (1.12,1.87) 1.75 (1.20,2.54) <0.0001
Model 1 0.65 (0.48,0.89) 1.00 1.05 (0.80,1.36) 1.37 (1.05,1.78) 1.71 (1.13,2.51) <0.0001
Model 2 0.67 (0.49,0.91) 1.00 1.05 (0.80,1.37) 1.35 (1.05,1.80) 1.65 (1.13,2.45) <0.0001
Model 1 Adjusted for age, smoking, physical inactivity, heavy drinking, social class, blood pressure, waist circumference, cholesterol, FEV1, renal function, diabetes, use of
antihypertensive drugs, LVH and CRP.
Model 2 Model 1 + QRS duration
Table 3
Incidence rates/1000 person years and adjusted relative hazard ratios (HR) and 95% CI for incident HF by height in 3346 men with no prevalent HF, stroke or MI.
Height (cms)
<168.2 (N = 841) 168.2–172.5 (N = 829) 172.6–176.9 (N = 849) 177.0–183.0 (N = 650) >183.0 (N = 177)
Rate/1000 (n) 8.8 (88) 5.1 (55) 6.6 (74) 6.1 (55) 8.8 (21)
Age adjusted 1.62 (1.15,2.26) 1.00 1.34 (0.94,1.89) 1.32 (0.91,1.92) 2.04 (1.23,3.39)
Model 1 1.65 (1.17,2.33) 1.00 1.35 (0.94,1.72) 1.25 (0.85,1.84) 1.87 (1.11,3.15)
Model 2 1.62 (1.14,2.30) 1.00 1.31 (0.92,1.88) 1.22 (0.83,1.80) 1.76 (1.04,2.96)
Model 3 1.69 (1.19,2.40) 1.00 1.30 (0.91,1.86) 1.19 (0.81,1.75) 1.63 (0.97,2.76)
Model 4 1.82 (1.28,2.59) 1.00 1.33 (0.92,1.90) 1.14 (0.78,1.69) 1.50 (0.89,2.55)
Model 1 adjusted for age, smoking, physical inactivity, heavy drinking, social class, waist circumference, blood pressure, cholesterol, FEV1, renal function, diabetes, use of
antihypertensive drugs , LVH, CRP
Model 2 = Model 1 + prevalent AF
Model 3 = Model 2 + QRS duration
Model 4 = Model 2 + incident AF
Fig. 1. Association of height (cms) with risk of incident heart failure: height modelled as restricted cubic splines with knots at the 5th (162cms) 25th, 50th, 75th and 95th
(183 cms) percentiles adjusted for age, smoking, physical activity, social class, waist circumference, diabetes, antihypertensive treatment, eGFR, LVH, heavy drinking, systolic
blood pressure and CRP.
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There was a curvilinear relationship between height and risk of
incident CHD (N = 424 cases) with those in the third quartile4
(172.6–176.9 cms) having the lowest risk; taller stature was not
associated with lower CHD risk. The age-adjusted HR (95 %CI) for
the 5 height groups were 1.23 (0.96,1.58), 1.00, 0.75 (0.57,0.99),
1.07 (0.79,1.46) and 0.99 (0.62,1.60) respectively. Adjustment for
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minor differences to the elevated risk seen in men with short sta-
ture [HR = 1.64 95% CI (1.17, 2.29)]4. Discussion
In this study of older men, we have confirmed previous obser-
vational studies on the association between tall stature and
increased risk of incident AF [3–9]. AF is strongly associated with
HF and our findings extend previous studies by examining whether
the association with height may influence HF risk in older tall
adults. We have shown that both short stature and tall stature
are associated with increased HF risk but the pathways underlying
these associations may be different. The increased risk of HF in
short adults was not explained by adverse CVD risk factors associ-
ated with short stature. By contrast, the increased risk of HF in tall
men was largely explained by their increased risk of AF and pro-
longed QRS duration, suggesting mechanisms linked to left ventric-
ular damage and the cardiac conduction system [11–13].4.1. Height and incident AF
In line with other observational studies we have shown tall sta-
ture to be associated with increased risk of AF [3–9] and this was
independent of known confounders including BMI and LVH. Indeed
height has already been included in clinical prediction score for AF
[3]. Adult height results from a combination of genetic and envi-
ronmental factors. It is relatively unclear how tall stature is related
to incident AF. It is suggested that the association may be linked to
the size of the left atrium of the heart which is known to be
strongly associated with body size and height and a major risk fac-
tor for the development of AF [5,28,29]. We did not have echocar-
diographic measurements. However, two previous reports have
shown the association between height and AF to be independent
of left atrial size [4,5,29] suggesting other pathophysiologic mech-
anisms. The association between height and AF may be related to
premature atrial contractions, a strong predictor of AF and associ-
ated complications [30]. Both small-scale and large scale genetic
studies have also shown associations between height associated
genetic variants and AF suggesting that the association is causal
[10,11,13] and may involve mechanisms associated with growth
pathways and AF.4.2. Height and electrocardiographic QRS duration
Height was significantly associated with the QRS duration, a
marker of ventricular depolarisation, as measured on the 12-lead
electrocardiogram. This finding is consistent with previous reports
showing QRS duration to be associated with greater body height
[11,12]. There is increasing evidence that a prolonged QRS duration
on the ECG is associated with increased risk of HF [14–17]. A QRS
duration < 100 ms has been considered normal. Over 50% of the tall
men who had no history of CVD or heart failure had QRS
duration > 100 ms compared to 22–35% in the other height groups
and they had the highest prevalence of men with a QRS duration
>=120 ms which is traditionally considered abnormal [26]. QRS
duration  120 ms may be a marker of increased left ventricular
(LV) mass but can also suggest functional abnormalities such as
LV dysfunction [26]. QRS prolongation may also be a manifestation
of ischemic injury to the myocardium, a common precursor of new
HF. However the tall men did not have raised hsTnT or NT-proBNP
(markers of cardiac injury). The strong association between tall
stature and prolonged QRS duration may reflect the known associ-
ation between height and LV mass [28].5
4.3. Height and incident HF
Although tall stature has been linked with incident AF, which is
strongly associated with HF, relatively few studies have examined
the association between height and incident HF. Despite the posi-
tive relationship between height and AF, previous studies have
reported an inverse association or no association between height
and incident HF. In contrast to previous studies we have shown
that both short men and in particular tall men were at increased
risk of developing HF. In tall men, the increased risk was largely
due their increased risk of developing AF and their increased risk
of having prolonged QRS duration. The difference in findings on
height and incident HF may be due to the difference in the popula-
tion age as the two studies reporting an inverse association were
conducted in middle-age. Height has been shown to be inversely
related to the development of CHD which in turn is associated with
reduced risk of developing HF. This was observed in these men in
an earlier report when the men were middle aged. Height mea-
sured when aged 40–59 yrs was inversely associated with 12 year
incident CHD with risk decreasing progressively with increasing
height [31]. However in older age (60–79 years) tall stature in
these men was not associated with reduced risk of subsequent
CHD. Older patients with HF differ from younger patients in that
a higher proportion of older HF patients have HF with preserved
ejection fraction [32]. These patients are less likely to have CHD
and more likely to have hypertension and atrial fibrillation which
becomes more prevalent in older adults [32]. Thus, despite the
increased risk of AF associated with taller stature seen in middle-
aged populations, the development of HF may not manifest until
later life. A high proportion of men without prior MI in this study
who developed HF did not have an MI before developing HF (85%),
which could explain the difference in findings between this and the
younger US cohorts previously studied. In contrast, CHD is the pre-
dominant risk factor for HF with reduced ejection fraction, which is
more common in younger adults [32]. This may explain the overall
lower risk of HF associated with tall stature seen in these two pre-
vious studies conducted in younger populations. Moreover, we
have observed that risk is significantly increased only in men over
183cms (6ft), which represented only a small proportion of men
aged 60–79 in this cohort of men born between 1919 and 1938.
This may also explain the absence of increased risk of HF in the
recent Korean study where the height in the top decile of the pop-
ulation was only 170cms [33]. Average body height has increased
over the decades [2]; if this trend continues, the prevalence of tall
older adults is likely to increase which may contribute to an
increasing burden of AF and HF.
By contrast short stature was associated with increased HF
despite lower risk of AF and this increased risk was not explained
by known adverse CVD risk factors. It is well documented that
short stature is associated with increased risk of CHD a major
determinant of HF [2]. However the association was not explained
by incident MI. The increased risk of HF in short people has been
observed in previous studies [33]. The physiological effect of short
stature on central haemodynamics and arterial tree may be an
explanation for the independent association between short stature
and HF [17,34]. Shorter adults have faster heart rates and increased
central aortic pressure leading to increased cardiac overloading
and diastolic dysfunction [34]. Short stature has also shown to
have physiological effects on the arterial tree, which increase left
ventricular pulsatile work and left ventricular mass and jeopar-
dize myocardial perfusion leading to a reduced venous flow to
the heart [17,34]. Alternatively, although adverse risk factors and
adult social class did not explain the increased risk in men with
short stature it is possible that the increased risk may be due to
factors associated with early life circumstances which determines
height. The increased risk may be explained by larger differences
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poorer hygiene and nutritional conditions in shorter people com-
pared to taller people rather than short status per se.5. Strengths and limitations
The study population is socially representative of the UK popu-
lation, and follow-up rates in the British Regional Heart Study are
very high [20] However it was based on an older predominantly
white male population of European extraction, so that the results
cannot be generalized directly to women, younger populations or
other ethnic groups. The current findings are based on doctor diag-
nosed HF, which is likely to underestimate the true incidence of HF
in this study population. However, the determinants of HF in this
study population (including obesity, NT-proBNP and lung function)
[21,22,24] generally accord with prior data and suggest that the HF
outcome used was valid. However, echocardiographic measure-
ments were not routinely carried out and we were not able to dif-
ferentiate systolic and diastolic HF. Our data was based on doctor
diagnosis of AF; tall people tend to be of higher social classes
and may be more likely to have their AF diagnosed. Thus the mag-
nitude of effect of tall stature on incident AF may have been over-
estimated. However, in a subset of men, taller people were also
more likely to develop AF on ECG at re-examination. Incident AF
was based on doctor diagnosis and evidence on ECG at the two
examination periods therefore we may not have detected those
with paroxysmal AF. However our findings accord with studies
where ECG was carried out annually [4]. Moreover the findings
are consistent with prior reports on height and AF in older adults
[4,8] and with previous studies using follow-up hospital registry
records [7]. Moreover adjustment for incident AF did attenuate
the association between tall stature and incident HF in this study.6. Conclusion
The study confirms the strong positive association between
height and increased risk of AF in older age. Tall stature is associ-
ated with increased risk HF in older adults which is to a large
extent explained by their increased risk of developing AF. Height
may serve as a marker for increased AF. Although adult height is
not a modifiable factor, height could be taken into account in risk
assessment of AF to improve screening for AF in older people,
which in turn may help decrease the risk of developing HF in tall
older adults.
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